Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThIlo-Trial: Iloprost for ARDS
NCT03111212Phase 3Completed
- Sponsor
- University Hospital Tübingen
- Start
- Jun 2019
- Primary completion
- May 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of iloprost in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by University Hospital Tübingen. Primary endpoint: Oxygenation Index (PaO2/FiO2) at Day 5. Started Jun 2019; status: completed.
02
Drugs
iloprost
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT03111212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03111212.